Co-Processed Excipients: Advances and Future Trends

Abstract

This review provides a concise overview of recent advances and future perspectives in co-processed excipients which is characterized by their synergistic combinations have become pivotal in pharmaceutical formulations. This review delves in to the latest innovations manufacturing techniques and applications of co-processed excipients. Emphasis is placed on enhanced functionality, and improved performance and the potential for addressing formulation challenges. The abstract concludes by highlighting the future prospects and emerging trends in this dynamic field, offering valuable insights for researchers and pharmaceutical professionals alike.

Keywords

Co-Processed excipients / Cancer / Oleic acid / Biologic medicinal products / Pharmaceutical ingredients / Bio

References

[1] Asmawi AA, Salim N, Ngan CL, et al. Excipient selection and aerodynamic characterization of nebulized lipid-based nanoemulsion loaded with docetaxel for lung cancer treatment. Drug Deliv. Translation.Res. 2019 Apr 15;9:543–554.

[2] Bowles BJ, Dziemidowicz K, Lopez FL, et al. Co-processed excipients for dispersible tablets-part 1: manufacturability. AAPS PharmSciTech. 2018 Aug;19:2598–2609.

[3] Benabbas R, Sanchez-Ballester NM, Bataille B, Sharkawi T, Soulairol I. Development and pharmaceutical performance of a novel co-processed excipient of alginic acid and microcrystalline cellulose. Powder Technol. 2021 Jan 22;378:576–584.

[4] Bhatia V, Dhingra A, Chopra B, Guarve K. Co-PEs: recent advances and future perspective. J Drug Deliv Sci Technol. 2022 Apr 6:103316.

[5] Chowdhury P, Nagesh PK, Hatami E, et al. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Colloid Interface Sci. 2019 Feb 1;535:133–148.

[6] Bin LK, Gaurav A, Mandal UK. A review on co-processed excipients: current and future trend of excipient technology. Int J Pharm Pharmaceut Sci. 2019.

[7] Yao K, McClements DJ, Xiang J, et al. Improvement of carotenoid bioaccessibility from spinach by co-ingesting with excipient nanoemulsions: impact of the oil phase composition. Food Funct. 2019;10(9):5302–5311.

[8] Ogawa K, Katsumi H, Moroto Y, Morishita M, Yamamoto A. Processing parameters and ion excipients affect the physicochemical characteristics of the stereocomplexformed polylactide-b-polyethylene glycol nanoparticles and their pharmacokinetics. Pharmaceutics. 2022 Mar 4;14(3):568.

[9] Markovic M, Ben-Shabat S, Aponick A, Zimmermann EM, Dahan A. Lipids and lipidp-rocessing pathways in drug delivery and therapeutics. Int J Mol Sci. 2020 May 4;21(9):3248.

[10] Pandey M, Choudhury H, Fern JL, et al. 3D printing for oral drug delivery: a new tool to customize drug delivery. Drug Deliv. Translation.Res. 2020 Aug;10:986–1001.

[11] (a) Barkat MA, Das SS, Pottoo FH, Beg S, Rahman Z. Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications. Curr Pharmaceut Des. 2020;26(11):1167–1180;b) Buya AB, Beloqui A, Memvanga PB, Préat V. Self-nano-emulsifying drug-delivery systems: from the development to the current applications and challenges in oral drug delivery. Pharmaceutics. 2020;12(12):1194.

[12] Geraldes DC, Beraldo-de-Araújo VL, Pardo BO, Pessoa Junior A, Stephano MA, de Oliveira-Nascimento L. Protein drug delivery: current dosage form profile and formulation strategies. J Drug Target. 2020;28(4):339–355.

[13] Collins MN, Nechifor M, Tanasă F, et al. Valorization of lignin in polymer and composite systems for advanced engineering applications–a review. Int J Biol Macromol. 2019;131:828–849.

[14] Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24:1–6.

[15] Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777–26791.

[16] Eleftheriadis GK, Katsiotis CS, Genina N, Boetker J, Rantanen J, Fatouros DG. Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology. Expet Opin Drug Deliv. 2020;17(8):1063–1068.

[17] Cho HJ. Recent progresses in the development of hyaluronic acid-based nanosystems for tumor-targeted drug delivery and cancer imaging. J Pharm Investigat. 2020;50:115–129.

[18] Garcia MA, Garcia CF, Faraco AA. Pharmaceutical and biomedical applications of native and modified starch: a review. Starch-Stärke. 2020;72(7–8):1900270.

[19] Arévalo-Pérez R, Maderuelo C, Lanao JM. Recent advances in colon drug delivery systems. J Contr Release. 2020;327:703–724.

[20] Crivelli B, Perteghella S, Bari E, et al. Silk nanoparticles: from inert supports to bioactive natural carriers for drug delivery. Soft Matter. 2018;14(4):546–557.

[21] Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci. 2021;42(10):857–869.

[22] Mouhid L, Corzo-Martínez M, Torres C, et al. Improving in vivo efficacy of bioactive molecules: an overview of potentially antitumor phytochemicals and currently available lipid-based delivery systems. J Oncol. 2017:2017.

[23] Shi C, Zhao H, Fang Y, Shen L, Zhao L. Lactose in tablets: functionality, critical material attributes, applications, modifications and co-processed excipients. Drug Discov Today. 2023:103696.

[24] Aziz A, Rehman U, Sheikh A, Abourehab MA, Kesharwani P. Lipid-based nanocarrier mediated CRISPR/CaS9 delivery for cancer therapy. J Biomater Sci Polym Ed. 2022:1–21.

[25] Radmoghaddam ZA, Honarmand S, Dastjerdi M, Akbari S, Akbari A. Lipid-based nanoformulations for TKIs delivery in cancer therapy. NanoSci Technol. 2022:11–27.

[26] Luiz MT, Dutra JA, Tofani LB, et al. Targeted liposomes: a nonviral gene delivery system for cancer therapy. Pharmaceutics. 2022;14(4):821.

[27] Amin M, Seynhaeve AL, Sharifi M, Falahati M, Ten Hagen TL. Liposomal drug delivery systems for cancer therapy: the rotterdam experience. Pharmaceutics. 2022;14(10):2165.

[28] Khan MI, Hossain MI, Hossain MK, et al. Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Appl Bio Mater. 2022;5(3):971–1012.

[29] Bigham A, Rahimkhoei V, Abasian P, et al. Advances in tannic acid-incorporated biomaterials: infection treatment, regenerative medicine, cancer therapy, and biosensing. Chem Eng J. 2022;432:134146.

[30] Van NH, Vy NT, Van Toi V, Dao AH, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano. 2022:100064.

[31] Rahman M, Almalki WH, Alrobaian M, et al. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expet Opin Drug Deliv. 2021;18(4):489–513.

[32] Kurakula M, Gorityala S, Moharir K. Recent trends in design and evaluation of chitosan-based colon targeted drug delivery systems: update 2020. J Drug Deliv Sci Technol. 2021;64:102579.

[33] Aanisah N, Wardhana YW, Chaerunisaa AY, Budiman A. Review on modification of glucomannan as an excipient in solid dosage forms. Polymers. 2022;14(13):2550.

[34] Tranová T, Macho O, Loskot J, Mužíková J. Study of rheological and tableting properties of lubricated mixtures of co-processed dry binders for orally disintegrating tablets. Eur J Pharmaceut Sci. 2022;168:106035.

[35] Abdelhamid M, Koutsamanis I, Corzo C, et al. Filament-based 3D-printing of placebo dosage forms using brittle lipid-based excipients. Int J Pharm. 2022:122013, 624.

[36] Gao Y, Li J, Zhao L, et al. Distribution pattern and surface nature-mediated differential effects of hydrophilic and hydrophobic nano-silica on key direct compaction properties of Citri Reticulatae Pericarpium powder by co-processing. Powder Technol. 2022;404:117442.

[37] Zupančič O, Spoerk M, Paudel A. Lipid-based solubilization technology via hot melt extrusion: promises and challenges. Expet Opin Drug Deliv. 2022;19(9):1013–1032.

[38] Nakmode D, Bhavana V, Thakor P, et al. Fundamental aspects of lipid-based excipients in lipid-based product development. Pharmaceutics. 2022;14(4):831.

[39] Dhaval M, Vaghela P, Patel K, et al. Lipid-based emulsion drug delivery systems—a comprehensive review. Drug Deliv Translation Res. 2022:1–24.

[40] Lazić I, Kučević S, Ćirin-Varađan S, Aleksić I, Đuriš J. Formulation of ibuprofenmodified release hydrophilic and lipid matrix tablets using co-processed excipients. Arhiv za farmaciju. 2022;72(4 suplement):S3400–S3401.

[41] Singh A, Ansari VA, Ahsan F, Akhtar J, Khushwaha P, Maheshwari S. Viridescent concoction of genstein tendentious silver nanoparticles for breast cancer. Res J Pharm Technol. 2021;14(5):2867–2872.

[42] Telange DR, Bhaktani NM, Hemke AT, et al. Development and characterization of pentaerythritol-EudragitRS100 Co-processed excipients as solid dispersion carriers for enhanced aqueous solubility, in vitro dissolution, and ex vivo permeation of atorvastatin. ACS Omega. 2023.

[43] Singh A, Ansari VA, Haider F, Akhtar J, Ahsan F. A review on topical preparation of herbal drugs used in liposomal delivery against ageing. Res J Pharmacol Pharmacodyn. 2020;12(1):5–11.

[44] Gao Y, Zeng Y, Liu X, Tang D. Liposome-mediated in situ formation of type-I heterojunction for amplified photoelectrochemical immunoassay. Anal Chem. 2022;94(11):4859–4865.

[45] Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372.

[46] Chavda VP, Vihol D, Mehta B, et al. Phytochemical-loaded liposomes for anticancer therapy: an updated review. Nanomedicine. 2022;17(8):547–568.

[47] Yanoff Z. The Effect of DNA Sequence on Oligonucleotide-Stabilized Lipid Micelles. 2022.

[48] Moosavian SA, Kesharwani P, Singh V, Sahebkar A. Aptamer-functionalized liposomes for targeted cancer therapy. Aptamers Eng Nanocarrier Cancer Ther. 2023:141–172.

[49] Mohammadi M, Hamishehkar H, McClements DJ, Shahvalizadeh R, Barri A. Encapsulation of Spirulina protein hydrolysates in liposomes: impact on antioxidant activity and gastrointestinal behavior. Food Chem. 2023;400:133973.

[50] Chen M, Wang S, Qi Z, et al. Deuterated colchicine liposomes based on oligomeric hyaluronic acid modification enhance anti-tumor effect and reduce systemic toxicity. Int J Pharm. 2023;632:122578.

[51] Akbari J, Saeedi M, Ahmadi F, et al. Solid lipid nanoparticles and nanostructured lipid carriers: a review of the methods of manufacture and routes of administration. Pharmaceut Dev Technol. 2022;27(5):525–544.

[52] Li Z, Yin Z, Li B, et al. Docosahexaenoic acid-loaded nanostructured lipid carriers for the treatment of peri-implantitis in rats. Int J Mol Sci. 2023 Jan;24(3):1872.

[53] Gugleva V, Andonova V. Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms. Pharmaceuticals. 2023;16(3):474.

[54] Wang H, Xue KF, Yang Y, Hu H, Xu JF, Zhang X. In situ hypoxia-induced supramolecular perylene diimide radical anions in tumors for photothermal therapy with improved specificity. J Am Chem Soc. 2022;144(5):2360–2367.

[55] Hu H, Wang H, Yang Y, Xu JF, Zhang X. A bacteria-responsive porphyrin for adaptable photodynamic/photothermal therapy. Angew Chem. 2022;134(23): e202200799.

[56] Li X, Yong T, Wei Z, et al. Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts. Nat Commun. 2022;13(1):2794.

[57] Lei Q, He D, Ding L, et al. Microneedle patches integrated with biomineralized melanin nanoparticles for simultaneous skin tumor photothermal therapy and wound healing. Adv Funct Mater. 2022;32(22):2113269.

[58] Chang M, Hou Z, Wang M, et al. Cu single atom nanozyme based high-efficiency mild photothermal therapy through cellular metabolic regulation. Angew Chem Int Ed. 2022;61(50):e202209245.

[59] Hu B, Cui Y, Yang X, Xu X, Janani BJ, Fakhri A. Fabrication of novel rational Ti-Sn doped Cu-ferrite nanoparticles for robust photocatalysis reaction, magnetic resonance imaging, and chemo-magneto-photo-thermal therapy. Surface Interfac. 2022;33:102226.

[60] Mo Z, Qiu M, Zhao K, et al. Multifunctional phototheranostic nanoplatform based on polydopamine-manganese dioxide-IR780 iodide for effective magnetic resonance imaging-guided synergistic photodynamic/photothermal therapy. J Colloid Interface Sci. 2022;611:193–204.

[61] Vila-Caballer M, Codolo G, Munari F, et al. A pH-sensitive stearoyl-PEG-poly (methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: an application for bladder cancer treatment. J Contr Release. 2016;238:31–42.

[62] Ray P, Dutta D, Haque I, et al. pH-sensitive nanodrug carriers for codelivery of ERK inhibitor and gemcitabine enhance the inhibition of tumor growth in pancreatic cancer. Mol Pharm. 2020;18(1):87–100.

[63] Zhong H, Mu J, Du Y, et al. Acid-triggered release of native gemcitabine conjugated in polyketal nanoparticles for enhanced anticancer therapy. Biomacromolecules. 2020;21(2):803–814.

[64] Czupiel P, Delplace V, Shoichet M. Nanoparticle delivery of a pH-sensitive prodrug of doxorubicin and a mitochondrial targeting VES-H8R8 synergistically kill multidrug resistant breast cancer cells. Sci Rep. 2020;10(1):8726.

[65] Cheng X, Zeng X, Zheng Y, Wang X, Tang R. Surface-fluorinated and pH-sensitive carboxymethyl chitosan nanoparticles to overcome biological barriers for improved drug delivery in vivo. Carbohydr Polym. 2019;208:59–69.

[66] Anandhan A, Dodson M, Schmidlin CJ, Liu P, Zhang DD. Breakdown of an ironclad defense system: the critical role of NRF2 in mediating ferroptosis. Cell Chem Biol. 2020 Apr 16;27(4):436–447.

[67] Lu J, Zhao Y, Liu M, Lu J, Guan S. Toward improved human health: nrf2 plays a critical role in regulating ferroptosis. Food Funct. 2021;12(20):9583–9606.

[68] Ergul M, Aktan F, Yildiz MT, Tutar Y. Perturbation of HSP network in MCF-7 breast cancer cell line triggers inducible HSP70 expression and leads to tumor suppression. Anti Cancer Agents Med Chem. 2020;20(9):1051–1060.

[69] Hoter A, Naim HY. Heat shock proteins and ovarian cancer: important roles and therapeutic opportunities. Cancers. 2019;11(9):1389.

[70] Yuan H, Pratte J, Giardina C. Ferroptosis and its potential as a therapeutic target. Biochem Pharmacol. 2021;186:114486.

[71] Zhu Q, Wu Y, Mai J, et al. Comprehensive metabolic profiling of inflammation indicated key roles of glycerophospholipid and arginine metabolism in coronary artery disease. Front Immunol. 2022;13:829425.

[72] Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Targeted Ther. 2020;5(1):108.

[73] Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Targeted Ther. 2021;6(1):74.

[74] Sun Y, Xue Z, Huang T, Che X, Wu G. Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy. Front Oncol. 2022;12:941618.

[75] Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10):1429.

[76] Tang D, Kroemer G, Kang R. Ferroptosis in immunostimulation and immunosuppression. Immunol Rev. 2023.

[77] Song X, Long D. Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front Neurosci. 2020;14:267.

[78] Liu X, Cui J, Gong L, et al. The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. Oncogene. 2020 Apr 23;39(17):3588–3603.

[79] Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33(25):3225–3234.

[80] Xu G, Chhangawala S, Cocco E, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52(2):198–207.

[81] Li Y, Feng X, Zhang Y, et al. Dietary flavone from the Tetrastigma hemsleyanum vine triggers human lung adenocarcinoma apoptosis via autophagy. Food Funct. 2020;11(11):9776–9788.

[82] Elmallah MI, Cordonnier M, Vautrot V, Chanteloup G, Garrido C, Gobbo J. Membrane-anchored heat-shock protein 70 (Hsp70) in cancer. Cancer Lett. 2020;469:134–141.

[83] Clemente SM, Martínez-Costa OH, Monsalve M, Samhan-Arias AK. Targeting lipid peroxidation for cancer treatment. Molecules. 2020;25(21):5144.

[84] Singh A, Ansari VA, Mahmood T, Ahsan F, Wasim R. Neurodegeneration: microglia: nf-kappab signaling pathways. Drug Research. 2022.

[85] Singh A, Ansari VA, Mahmood T, et al. Receptor for advanced glycation end products: dementia and cognitive impairment. Drug Research. 2023.

[86] Wasim R, Mahmood T, Siddiqui MH, et al. Aftermath of AGE-RAGE Cascade in the pathophysiology of cardiovascular ailments. Life Sci. 2022:120860.

[87] Maheshwari S. AGEs RAGE pathways: alzheimer’s disease. Drug Research. 2023.

[88] Li Q, Chen X, Lin W, Guo X, Ma Y. Application of a novel multicomponent nanoemulsion to tumor therapy Based on the theory of “unification of drugs and excipients”. Pharmaceut Dev Technol. 2023;28(3–4):351–362.

[89] Thompson SA, Gala U, Davis Jr DA, Kucera S, Miller D, Williams III RO. Can the oral bioavailability of the discontinued prostate cancer drug galeterone Be improved by processing method? KinetiSol® outperforms spray drying in a head-to-head comparison. AAPS PharmSciTech. 2023;24(6):137.

[90] Awad A, Goyanes A, Basit AW, et al. A review of state-of-the-art on enabling additive manufacturing processes for precision medicine. J Manuf Sci Eng. 2023;145(1):010802.

[91] Zheng YD, Ma LM, Lu JJ, et al. Nardoguaianone L isolated from nardostachys jatamansi improved the effect of gemcitabine chemotherapy via regulating AGE signaling pathway in SW1990 cells. Molecules. 2022;27(20):6849.

[92] Huang J, Chen B, Wang H, et al. Dihydromyricetin attenuates depressive-like behaviors in mice by inhibiting the AGE-RAGE signaling pathway. Cells. 2022;11(23):3730.

[93] Kadonosono T, Miyamoto K, Sakai S, et al. AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures. Sci Rep. 2022;12(1):9886.

[94] Moulahoum H, Ghorbanizamani F, Khiari Z, et al. Artemisia alleviates AGE-induced liver complications via MAPK and RAGE signaling pathways modulation: a combinatorial study. Mol Cell Biochem. 2022;477(10):2345–2357.

[95] Lu D, Shang J, Guo X, Zhang Y. Assessing the mechanism of action of “Fructus Ligustri Lucidi-Cuscutae Semen” in prostate cancer treatment using network pharmacology and molecular docking. Comput Math Methods Med. 2022 Oct 25:2022.

[96] Waqas K, Muller M, Koedam M, El Kadi Y, Zillikens MC, van der Eerden BC. Methylglyoxal-an advanced glycation end products (AGEs) precursor-Inhibits differentiation of human MSC-derived osteoblasts in vitro independently of receptor for AGEs (RAGE). Bone. 2022;164:116526.

[97] Holms RD. Long COVID (PASC) is maintained by a self-sustaining pro-inflammatory TLR4/RAGE-loop of S100a8/a9> TLR4/RAGE signalling, inducing chronic expression of IL-1b, IL-6 and TNFa: anti-inflammatory ezrin peptides as potential therapy. Immunotherapy. 2022 Sep 8;2(3):512–533.

[98] Kinscherf NA, Pehar M. Role and therapeutic potential of RAGE signaling in neurodegeneration. Curr Drug Targets. 2022;23(12):1191.

[99] Ren L, Yan H. Targeting AGEs-RAGE pathway inhibits inflammation and presents neuroprotective effect against hepatic ischemia-reperfusion induced hippocampus damage. Clin Res Hepatol Gastroenterol. 2022;46(2):101792.

[100] Rowe MM, Wang W, Taufalele PV, Reinhart-King CA. AGE-breaker ALT711 reverses glycation-mediated cancer cell migration. Soft Matter. 2022;18(44):8504–8513.

RIGHTS & PERMISSIONS

2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.